Clinical Trial Update: Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of CTAP101, immediate-release calcifediol, high-dose cholecalciferol, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism Due to Renal Causes
• Vitamin Deficiency Insufficiency

Drugs mentioned

• CTAP101
• Calcifediol (immediate-release) (calcifediol)
• Cholecalciferol (high-dose) (vitamin D3)
• Low-dose cholecalciferol (vitamin D3)
• Paricalcitol (paricalcitol)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency | Phase 4 | Status: COMPLETED | Results posted: 2022-12-09